Loading
A phase 3 trial of Trilaciclib in small-cell lung cancer, run by Pharmacosmos A/S, now recruiting.
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07473128 by Pharmacosmos A/S, with 120 participants planned, started 2026-06-30 and due to reach its primary completion in 2027-06. Interventions recorded: Trilaciclib, Saline (0.9% NaCl). Conditions listed: Limited Stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Trilaciclib, Small-cell lung cancer.
Shares Limited-stage small-cell lung cancer, Small-cell lung cancer.
Shares Limited-stage small-cell lung cancer, Small-cell lung cancer.
Shares Trilaciclib, Small-cell lung cancer.
Shares Limited-stage small-cell lung cancer, Small-cell lung cancer.
Shares Limited-stage small-cell lung cancer, Small-cell lung cancer.
Shares Limited-stage small-cell lung cancer, Small-cell lung cancer.
Shares Limited-stage small-cell lung cancer, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/